Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X:
“Not all SERDs beat aromatase inhibitors. Phase III persevERA shows giredestrant + palbociclib did not improve PFS vs letrozole + palbociclib.
Trial essentials
- Phase III, randomized, double-blind
- N = 992 patients
- 1L ER+/HER2- metastatic breast cancer
- Primary endpoint – progression-free survival
Trial arms
Giredestrant + palbociclib, Letrozole + palbociclib
Key result: Primary endpoint not met No statistically significant improvement in PFS.
A numerical PFS improvement was observed but did not reach statistical significance.
Safety
Adverse events were consistent with known safety profiles of endocrine therapy plus CDK4/6 inhibition.
Clinical context
Giredestrant is being tested across multiple phase III trials in ER+ disease including lidERA, evERA, and pionERA.
Takeaway
persevERA may be negative, but next-generation oral SERDs remain a major development strategy in ER+ breast cancer.
Save this if you follow SERD development in breast cancer.”
Other articles featuring Rishabh Jain on OncoDaily.
